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Background: Protamine reversal of heparin anticoagulation often causes 
systemic hypotension, and in vitro studies uggest that this may be mediated by 
release of nitric oxide from the endothelium. The present investigations were 
designed to evaluate the direct myocardial effects of protamine and to 
determine in vivo whether nitric oxide inhibition can prevent hypotension 
during protamine infusion. Methods~Results: Protamine sulfate (50/xg/ml) was 
added to perfusate of eight isolated rabbit heart preparations; in six other 
preparations, a similar concentration ofprotamine was added to heparinized (5
U/ml) Krebs perfusate. Left ventricular developed pressure, maximum rate of 
pressure rise, and heart rate declined significantly (p < 0.01) in hearts exposed 
to protamine only (65.0% - 6.6%, 55.5% -+ 6.0%, and 87.6% - 2.5% of baseline, 
respectively), whereas protamine added to heparinized perfusate caused little 
change in developed pressure, maximum rate of pressure rise, and heart rate 
(85.3% - 5.4%, 84.9% _ 5.5%, and 98.8% -.+ 1.6%). To study systemic effects of 
protamine, we measured hemodynamic parameters in 12 heparinized ogs 
(150 U/kg). During protamine infusion (1.5 mg/kg intravenously over 30 
seconds), mean blood pressure decreased by 46% - 7% from baseline (p < 
0.05), cardiac output decreased by 38% -+ 4% (p < 0.05), and systemic vascular 
resistance decreased by 14% - 9%. After hemodynamic stabilization, N g- 
monomethyl-L-arginine (2 mg/kg), a competitive inhibitor of nitric oxide 
synthesis, was administered to six dogs, and methylene blue (2 mg/kg), an 
inhibitor of cyclic guanosine monophosphate synthesis, was administered to 
the remaining six dogs. After treatment with N~-monomethyl-L-arginine a d
methylene blue, the second infusion fprotamine sulfate caused no significant 
change in blood pressure or cardiac output. In an additional six dogs, 
N~-monomethyl-L-arginine pretreatment (5 mg/kg) blocked the effects of the 
first dose of protamine. The effect of Ng-monomethyl-L-arginine could be 
reversed by the addition of (6 mg/kg) ~-arginine but not D-arginine. Conclu- 
sions: Protamine-heparin complex does not cause direct myocardial depression 
but does lead to severe hypotension i vivo. The finding that hypotension can 
be blocked by inhibitors of the nitric oxide pathway confirms previous in vitro 
studies indicating that the effects of protamine are mediated, in part, by the 
vascular endothelium. Further, these studies suggest a novel approach to 
prevention of hemodynamic complications caused by heparin reversal after 
cardiopulmonary b pass. (J Thorac Cardiovasc Surg 1996;111:1240-7) 
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p rotamine sulfate is a polycationic protein used to 
reverse the anticoagulant effect of heparin in 
cardiovascular operations, t The action of protamine 
is thought to result from the one-to-one cationic- 
anionic pairing with heparin to achieve reversal. 2-5 
However, the use of protamine has been associated 
with numerous clinically significant side effects, in- 
cluding systemic hypotension, pulmonary vasocon- 
striction, and anaphylaxis. 6-8 The most common 
untoward effect is systemic hypotension, and reports 
of hypotensive reactions to protamine have become 
more frequent with the widespread use of cardiac 
catheterization and cardiopulmonary bypass. 9-13 
Such adverse reactions can be especially dangerous 
in the period immediately after extracorporeal cir- 
culation if cardiac function is impaired. Thus pre- 
vention of hypotension during protamine adminis- 
tration is especially important o cardiac surgeons 
and anesthesiologists. 144s 
Recent evidence suggests that protamine has a 
direct effect on myocytes. Hird and colleagues t9
demonstrated that in isolated myocyte preparations, 
unbound protamine directly depresses myocyte con- 
tractility and blunts its/3-adrenergic responsiveness; 
importantly, the heparin-protamine complex did not 
have this effect. Furthermore, studies from our 
laboratory by Pearson and associates 2°established a 
possible mechanism for vasodilation i response to 
protamine; in vitro, protamine stimulates release of 
nitric oxide from the vascular endothelium. 
In light of these recent findings, we designed the 
present experiments to evaluate further the direct 
myocardial and systemic effects of protamine and to 
examine whether the vascular endothelial release of 
nitric oxide plays a role in the development of 
hypotension in vivo. 
Materials and methods 
To study the central and systemic effects of protamine 
sulfate infusion, we performed two sets of experiments. 
First, in vitro isolated rabbit hearts were used to evaluate 
the effect of protamine on myocardial function. Second, 
an intact canine preparation was used to determine the 
systemic hemodynamic effects of protamine. All animals 
received humane care in compliance with the "Guide for 
the Care and Use of Laboratory Animals" published by 
the National Institutes of Health (NIH Publications No. 
85-23, revised 1985), and protocols were approved by the 
Institutional Animal Care and Use Committee of the 
Mayo Foundation. 
Modified Langendorlf preparation (in vitro studies). 
Adult New Zealand White rabbits (either sex, 3.0 to 4.0 
kg) were anesthetized by intravenous injection of pento- 
barbital (35 mg/kg body weight), and cardiectomy was 
performed. Beating hearts were immediately placed in a 
cold (4 ° C) modified Krebs-Ringer-bicarbonate (KRB) 
solution of the following millimolar composition: NaC1, 
118.3; KC1, 4.7; MGSO4,1.2; KH2PO4, 1.22; CaC12, 2.5; 
NaHCO3, 25.0; and glucose, 11.1. Hearts were then 
suspended from a Langendorff perfusion column, and 
retrograde perfusion was established at 37°C with an 
overflow system to maintain aconstant coronary perfusion 
pressure of 70 mm Hg. The time delay between harvest 
and perfusion of all hearts was kept to less than 2 minutes. 
The nonrecirculating KRB perfusate was bubbled with a 
95% oxygen and 5% carbon dioxide gas mixture to 
achieve aperfusate oxygen tension more than 600 mm Hg 
and pH 7.4, and the solution was filtered. After retrograde 
perfusion was established, the free wall of the left atrium, 
the mitral valve leaflets, and the chordae tendineae were 
excised to vent the left ventricle and permit insertion of an 
oversized intraventricular balloon; this was attached to a 
flange, which was secured to the mitral valve anulus. A 
water-filled tube (PE190; Clay-Adams, Becton-Dickinson 
Co., Parsippany, N.J.) connected the balloon to a trans- 
ducer (Gould 2400, Gould, Inc., Cleveland, Ohio) for 
measurement of left ventricular developed pressure, the 
maximal rate of rise of left ventricular p essure (dp/dt), 
and heart rate. Timed collections of coronary effluent 
were made for measurement of coronary flow rate. 
Protocol. Hearts were randomly divided into two 
groups. In the protamine group (n = 8), hearts were 
stabilized for 20 to 30 minutes and then exposed to 
protamine at a final concentration f 50/xg/ml (protamine 
sulfate, Lyphomed, Inc., Rosemont, Ill.) for 20 minutes 
(experimental period). In the heparin-protamine group 
(n = 6), the hearts were exposed to protamine in the same 
manner as the first group; however, the KRB solution 
contained 5 U/ml concentration f heparin (heparin so- 
dium, Elkins-sinn, Inc., Cherry Hill, N.J.) throughout the 
experiment. A 50 txg/ml dose of protamine is approxi- 
mately equal to 4 mg/kg of body weight and can reverse a
heparin concentration of 5 U/ml, which is approximately 
equal to 400 U/kg of body weight. This concentration of
heparin is similar to that used during cardiopulmonary 
bypass. 
Left ventricular developed pressure, dp/dt, heart rate, 
and coronary flow rate were measured just before (base- 
line) and after exposure to protamine (at 3, 5, 10, 15, and 
20 minutes). Addition of heparin or protamine, or both, 
did not alter the other constituents of the KRB solution. 
Data analysis. The results were expressed as percent 
change from control, and data are summarized as mean _+ 
standard error of the mean. Statistical evaluation was 
performed by means of two-way analysis of variance for 
comparing time-related changes between groups. Then, 
pairwise comparisons were made by means of the 
Newman-Keuls multiple comparisons test. Differences 
were considered to be statistically significant when the p 
value was less than 0.05. 
Canine experiments (in vivo studies). In vivo experi- 
ments were performed in 20 heartworm-free mongrel 
dogs (25 to 32 kg) anesthetized with pentobarbital sodium 
(30 mg/kg total dose). All dogs underwent median ster- 
notomy and were monitored with a femoral arterial 
catheter to measure blood pressure. A Swan-Ganz pulmo- 
1242 Raikar et al. 





Ho0ar'n 1,0u,k0 J [pro,am,no,. m0,k  




n=2 1 :ol 01 Heparin 150u/kg L=arginine or ~ I LoNMMA 5mg/kg D-arg nine 6mg/kg ~ Protamine lo5mg/k 
Fig. 1. Protocol for in vivo experiments, n, Number of animals tudied. 
nary artery catheter (Baxter Healthcare Corp., Edwards 
Div., Santa Ana, Calif.) was used to monitor intracardiac 
pressures and to measure cardiac output by the thermodi- 
lution method. Hydration in the animals was maintained 
by constant intravenous infusion of Ringer's lactate solu- 
tion (10 ml/min) throughout the experiment. Standard 
hemodynamic measurements including heart rate, sys- 
temic and pulmonary arterial blood pressures, right atrial 
pressure, and cardiac output were made before and after 
each intervention. 
Protocol. The study protocol is shown in Fig. 1. The 
first group of 12 dogs was given an intravenous heparin 
dose of 150 U/kg (heparin sodium, Elkins-sinn, Inc.), 
and 30 minutes later protamine sulfate, 1.5 mg/kg 
(protamine sulfate, Lyphomed, Inc.), was administered 
intravenously over 30 seconds. These doses of heparin 
and protamine corresponded to one-to~one reversal. 
After stabilization from the first dose of protamine, 
Ng-monomethyl-L-arginine 10 -3 (L-NMMA) (2 mg/kg) 
(Calbiochem, San Diego, Calif.), a competitive inhibi- 
tor of nitric oxide synthesis from ~-arginine, was admin- 
istered as a bolus infusion in six dogs, and methylene 
blue (2 mg/kg) (Sigma Chemical Company, St. Louis, 
Mo.), an inhibitor of cyclic guanosine monophosphate, 
was administered in the other six dogs. 
To control for possible confounding effects of repeated 
protamine administration, we studied an additional six 
dogs. Animals were heparinized (150 U/kg) and then 
pretreated with L-NMMA before protamine reversal of 
heparin. In two additional dogs, ~-arginine and D-arginine 
were administered to overcome the blockade of 
L-NMMA. 
Data analysis. Results were expressed as percent 
change from the control (preintervention) value and are 
summarized as means _+ standard error of mean. Data 
were analyzed by means of two-way analysis of variance 
and Student's t test when appropriate. Differences were 
considered to be statistically significant when p was less 
than 0.05. 
Results 
In vitro studies. During the 20-minute study pe- 
riod, left ventricular developed pressure, maximum 
dp/dt, and heart rate declined significantly in a 
time-dependent manner in the isolated hearts ex- 
posed to protamine only (65.0% ± 6.6%, 55.5% ± 
6.0%, and 87.6% ± 2.5% of baseline at 20 minutes, 
respectively). As seen in Fig. 2, these adverse ffects 
of protamine were attenuated by heparin. In hearts 
perfused with heparinized KRB, protamine caused 
little change in left ventricular developed pressure, 
maximum dp/dt, and heart rate (85.3% _ 5.4%, 
84.9% ± 5.5%, and 98.8% ± 1.6% of baseline, respec- 
tively), and the differences between groups with and 
without heparin were statistically significant (p < 0.01 
by two-way analysis of variance). In contrast o other 
variables, coronary flow was well preserved (91.4% ± 
8.1%) in the protamine group and in the protamine- 
heparin group (84.7% _+ 5.6%). 
In vivo studies. Without pretreatment, prota- 
mine reversal of heparin caused a significant de- 
crease in mean blood pressure (decrease of 46% ± 
7% from baseline, p < 0.05), cardiac output (de- 
crease of 38% ± 4% from baseline, p < 0.05), and 
systemic vascular esistance (decrease of 14% ± 9% 
of baseline). In these dogs, L-NMMA and methylene 
blue markedly attenuated the hemodynamic distur- 
bance after the second dose of protamine (Fig. 3). 
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Fig. 2. Effect of protamine-heparin complex on left ventricular developed pressure (LVDP), maximum 
dp/dt, and heart rate. The protamine group showed a significant decline during the 20-minute xperimental 
period (p < 0.01, one-way nalysis of variance). The presence of heparin attenuated protamine's effect. 
There is a statistically significant difference between the two groups (p < 0.01, two-way analysis of
variance). 
In the dogs pretreated with L-NMMA, the initial 
dose of protamine had little effect on systemic 
hemodynamics (mean arterial pressure decreased 
3% -+ 6%, cardiac output decreased 5% _+ 5%, and 
systemic vascular resistance rose 4% _+ 8% from 
baseline) (Fig. 4). 
An additional two dogs received pretreatment 
with I~-NMMA; administration of ].-arginine over- 
came the effect of the competitive blocker, and 
protamine caused hypotension. However, blood 
pressure remained stable when D-arginine was given 
to overcome competitive inhibition of nitric oxide 
synthase (Fig. 5). 
Discussion 
The administration of protamine to reverse hep- 
arin may lead to systemic hypotension, and this can 
be a catastrophic event early after cardiopulmonary 
bypass, especially in patients with impaired ventric- 
ular function. Numerous studies have investigated 
possible mechanism(s) for these adverse reactions. 















Fig. 3. Results from the initial response to protamine are 
designated as control and are compared with the hemo- 
dynamic measurements to repeated protamine infusion 
after treatment with L-NMMA (n = 6) or methylene blue 
(n = 6). Mean arterial pressure (MAP) and cardiac output 
(CO) are maintained as compared with control animals 
receiving only protamine (n = 12) (p < 0.05, Student's t 
test). Although the systemic vascular esistance (SVR) is 
not decreased as in hearts receiving only protamine, the 
difference is not statistically significant. 
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Fig. 4. Results from the initial response to protamine are 
shown as control. These are compared with the hemody- 
namic measurements seen after pretreatment of the dogs 
with I.-NMMA (5 mg/kg) (n = 6). Mean arterial pressure 
(MAP) and cardiac output (CO) are well preserved in the 
~-NMMA group, and this difference is statistically signif- 
icant (p < 0.05 Student's t test). Systemic vascular esis- 
tance (SVR) does not decrease as in the control group, but 
this difference is not statistically significant. 
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Fig. S. Results from two dogs are shown. Percent change 
of mean arterial pressure from baseline is compared inan 
animal receiving L-arginine (6 mg/kg) to an animal receiv- 
ing D-arginine (6 mg/kg) to overcome the blockade by 
L-NMMA pretreatment. The animal receiving L-arginine 
has profound systemic hypotension (decrease of 55% 
from baseline) on protamine infusion. The response to 
protamine is less in the animal receiving ~)-arginine (de- 
crease of 15% from baseline). 
suggested that protamine alone could cause dose- 
and time-dependent decrements in myocardial per- 
formance in the isolated rabbit heart. However, 
their investigation did not examine the effects of the 
heparin-protamine complex on myocardial function. 
More recently, Hird and associates 19demonstrated 
in isolated myocyte preparations that unbound pro- 
tamine directly depresses myocyte contractility and 
blunts its/3-adrenergic responsiveness, but the hep- 
arin-protamine complex did not have this effect. 
To assess the myocardial effects of the heparin- 
protamine complex, we used an isovolumic rabbit 
heart model. The concentration of heparin and 
protamine in the protocol closely paralleled the 
clinical use of anticoagulation and allowed us to 
examine the effects of the protamine and heparin in 
a beating heart. 
In these experiments, measures of left ventricular 
performance (developed pressure and maximum 
dp/dt) were significantly reduced when the rabbit 
hearts were exposed to protamine alone. These 
parameters changed very little when protamine was 
added to heparinized perfusate. Importantly, the 
model provides isovolumic measures of ventricular 
performance and a constant perfusion pressure; 
these features are critical in evaluation of com- 
pounds that have effects on systemic vascular esis- 
tance. It appears, therefore, that the protamine- 
heparin complex has little direct myocardial effect. 
These results are also consistent with the clinical 
observations of less hemodynamic disturbance with 
slow administration of protamine versus rapid infu- 
sion and less hemodynamic disturbance with in- 
traaortic administration compared with intravenous 
infusion.16, 18 It is possible that with rapid infusion, 
especially rapid intravenous infusion, uncomplexed 
protamine is presented to the coronary circulation 
("first pass" effect), and the resulting direct myocar- 
dial depression may aggravate hypotension caused 
by reduction in systemic vascular esistance. Slow 
infusion of protamine and intraaortic administration 
minimize the chance that unbound protamine will 
enter the coronary circulation. 
Clinical studies by Shapira and coworkers 6 re- 
ported that the major hemodynamic consequence of
protamine administration early after cardiopulmo- 
nary bypass was peripheral vasodilatation. In that 
study, 10 patients (45%) had mild peripheral vaso- 
dilatation with an increase in cardiac output suffi- 
cient to prevent a reduction of blood pressure. In 
contrast, peripheral vasodilatation was more pro- 
found in the remaining 12 patients (55%) and was 
associated with impairment of myocardial contrac- 
tility, as evidenced by a decrease in contractile 
element velocity. Thus all patients tudied had some 
change in peripheral vascular esistance. This find- 
ing, along with the in vitro studies by Pearson and 
colleagues, 2° which showed that protamine can 
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cause arterial vasorelaxation by endothelial release 
of nitric oxide, suggest that the effect of protamine 
in human beings might, in a large part, be due to 
peripheral vasodilatation. 
In our canine model, administration of a 1.5 
mg/kg dose of protamine consistently led to pro- 
found hypotension (mean decrease of 46% from 
baseline). When pretreated with a specific, compet- 
itive inhibitor of the nitric oxide pathway, N-NMMA, 
hemodynamic parameters after protamine infusion 
remained stable. The competitive inhibition of nitric 
oxide synthase was overcome by the addition of 
L-arginine and not ~>arginine. These are the first in 
vivo studies to implicate nitric oxide release with 
protamine-induced hypotension. 
It is tempting to ascribe the systemic hypotension 
in experiments oa direct action of protamine on the 
peripheral vasculature mediated by nitric oxide re- 
lease. However, the precise mechanism may be 
more complicated. In prior in vitro studies, a° the 
time course of the effect of protamine on systemic 
vessels was gradual, and complete relaxation to a 
bolus infusion of protamine required at least 10 
minutes. Systemic hypotension observed in these in 
vivo experiments (and that seen in human beings) 
occurs much more quickly, usually within 2 minutes 
after protamine infusion. Perhaps nitric oxide re- 
lease is the final mediator of hypotension during 
protamine infusion in clinical practice, and the 
triggering events are initiated by other humoral 
pathways. 
Also unexplained was the finding that in the 
canine experiments we noted a greater decrease in 
cardiac output han would be expected with changes 
in peripheral resistance alone. In the rabbit heart 
preparation, protamine, but not the protamine- 
heparin complex, led to a decrease in myocardial 
performance independent of preload and afterload 
variations. It is possible that a relatively small de- 
crease in arterial and venous tone decreases ventric- 
ular filling, which in turn reduces cardiac output and 
worsens hypotension. Also, there may be a second- 
ary myocardial effect of protamine resulting from 
myocardial ischemia caused by a fall in coronary 
perfusion pressure. Finally, it is possible that there is 
direct myocardial depression in our canine experi- 
ments that is species pecific and thus different from 
the rabbit model. 
Another explanation for the marked reduction in 
cardiac output is pulmonary vasoconstriction. Cer- 
tainly pulmonary vasoconstriction might reduce fill- 
ing of the left side of the heart and thereby reduce 
cardiac output. This investigation was not designed 
to precisely quantify changes in pulmonary hemody- 
namics and in vivo cardiac function during prota- 
mine infusion. Current studies in our laboratory do 
address these important effects of protamine. 
Other mechanisms that might be involved in 
protamine-induced hypotension were not evaluated 
in our protocol. The arachidonic acid pathway and 
its metabolites have been implicated as mediators of 
protamine-induced pulmonary vasoconstriction by 
Wakefield and colleagues. 23In human beings, pro- 
tamine clearly causes complement activation. 7 By- 
products or end products of these pathways (or 
both) may play a role in protamine-induced hypo- 
tension, and further investigation i to their relation- 
ship to nitric oxide release is warranted. 
Summary 
This investigation suggests that uncomplexed pro- 
tamine has a significant negative inotropic effect, but 
the protamine-heparin complex causes minimal 
myocardial depression of the intact myocardium. 
Furthermore, systemic hypotension might occur as a 
result of endothelial release of nitric oxide in vivo, 
and this can be attenuated by inhibition of the nitric 
oxide pathway. This is the first study to suggest that 
the nitric oxide pathway might be an important 
mediator of adverse reactions attributed to prota- 
mine in vivo and offers a novel approach to preven- 
tion of hypotension caused by heparin reversal after 
cardiopulmonary b pass. 
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Discussion 
Dr. Walter P. Dembitsky (San Diego, Calif.). The 
experiments presented are somewhat complicated, 
making statistical analysis also somewhat complicated. 
Nonetheless, according to our statistician, the conclu- 
sions should remain the same. In the series of in vitro 
studies in which a modified Langendorff preparation 
was used to analyze the function of rabbit hearts, it 
seems clear that protamine does directly suppress myo- 
cardial function. The suppression is not present when 
protamine is combined with heparin. It is intriguing that 
the coronary blood flow remains unchanged despite 
reductions in major determinants of myocardial oxygen 
consumption, heart rate, developed left ventricular 
pressure, and peak dp/dt. This suggests that the coro- 
nary autoregulation is disturbed. Does protamine dilate 
coronary arteries as well? 
Dr. Raikar. In vitro studies by Pearson and colleagues 
demonstrate that protamine alone can cause coronary 
vasorelaxation. In vivo, there might be a chance for 
uncomplexed protamine to be seen by the coronary 
circulation. The protamine-heparin complex, however, 
does not seem to have direct effects on the coronary 
circulation. 
Dr. Dembitsky. The clinical phenomenon of transient 
reduction of blood pressure after heparin administra- 
tion is common and is undoubtedly more significant in 
patients with compromised cardiac function. It does 
appear from your work that this hypotension can be 
induced by the direct or indirect influences of prota- 
mine on the peripheral vascular elease of nitric oxide. 
You suggest here may be novel approaches that inter- 
fere with nitric oxide release and prevent protamine- 
induced hypotension. I wonder if reduction in systemic 
vascular esistance in human beings is the most impor- 
tant determinant of systemic hypotension. The time 
required in vitro for protamine to gradually and maxi- 
mally relax the systemic vessels is about 10 minutes. 
This is often longer than experienced clinically and 
longer than you saw in your in vivo experiments. The 
fall in cardiac output you observe is greater than you 
expected with the changes in systemic vascular resis- 
tance. In your canine preparation, you did measure the 
pulmonary artery pressure and cardiac output and 
could have measured pulmonary capillary wedge pres- 
sure. The pulmonary data were not included in the 
manuscript. Did you determine the changes in pulmo- 
nary vascular esistance in your experiments? 
Dr. Raikar. We measured changes in pulmonary vascu- 
lar resistance primarily through changes in right atrial 
pressure in the open chest dog. There was a tendency 
toward a decrease in filling pressures in these animals. 
Current studies in our laboratory have implemented more 
sensitive measures of cardiac function (Emax) and of the 
pulmonary vasculature. 
Dr. Dembitsky. In our clinical experience, the periph- 
eral vasodilatation and myocardial suppressive ffects 
of protamine seem to be more easily managed than the 
occasional episodes of severe pulmonary vasoconstric- 
tion, which can produce severe systemic hypotension. 
Although this can often be an allergic phenomenon, 
pulmonary vasoconstriction may also be mediated 
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through other humoral mechanisms that can simulta- 
neously produce systemic hypotension. Vasoactive me- 
diators may exert their influence before the delayed 
protamine-nitr ic oxide interaction you have docu- 
mented. Do you consider the relation of protamine 
administration and systemic hypotension i dogs to be a 
direct or indirect effect? 
Dr. Raikar. From the present studies we can conclude 
that there is probably an indirect mechanism at work. 
Certainly other studies have shown that complement 
activation and the arachidonic acid pathway are also 
mediators involved in these reactions, and perhaps nitric 
oxide is the final mediator of these adverse reactions. 
Dr. Dembitsky. Do you think interfering with endothelial 
nitric oxide release can cause pulmonary hypertension? 
Dr. Raikar. Perhaps in higher doses of L-NMMA this 
might occur. In vivo studies of endothelium-induced s p- 
sis have used very high doses (20 to 30 mg/kg) of L- 
NMMA. Our studies used doses of 2 to 5 mg/kg, and at 
these doses we have not observed any pulmonary hyper- 
tension. 
Dr. Dembitsky. Last, what do you think the relevance of 
your canine findings are in human beings? 
Dr. Raikar. I think it is an important first step to 
evaluate the clinical use of L-NMMA and other block- 
ers of the nitric oxide pathway. We are in the process of 
concluding another study in the canine model, and 
studies in patients undergoing cardiopulmonary b pass 
will enlighten us as to the efficacy of these new modal- 
ities. 
